Cargando…
MPL Adjuvant Contains Competitive Antagonists of Human TLR4
Monophosphoryl lipid A (MPL(®)) is the first non-alum vaccine adjuvant to achieve widespread clinical and market acceptance, a remarkable achievement given that it is manufactured from a Salmonella enterica endotoxin. To understand how MPL(®) successfully balanced the dual mandate of vaccine design—...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596181/ https://www.ncbi.nlm.nih.gov/pubmed/33178204 http://dx.doi.org/10.3389/fimmu.2020.577823 |